# Anlotinib Combined With Docetaxel Versus Docetaxel for Previous Treated Advanced NSCLC

> **NCT03726736** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Yong Fang** · enrollment: 97 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Anlotinib combined Docetaxel
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT03726736
- **Lead sponsor:** Yong Fang
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-21
- **Primary completion:** 2019-11-01
- **Final completion:** 2020-11-01
- **Target enrollment:** 97 (ESTIMATED)
- **Last updated:** 2019-06-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03726736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03726736, "Anlotinib Combined With Docetaxel Versus Docetaxel for Previous Treated Advanced NSCLC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03726736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*